Floatz logo

Brentuximab Vedotin

Hodgkin'S Lymphoma, Lymphocytic-Histiocytic Predominance

National Cancer Institute (NCI)antibody_drug_conjugatePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Hodgkin'S Lymphoma, Lymphocytic-Histiocytic Predominance cohort.

Asset / SponsorPhaseRating
VINBLASTINE
National Cancer Institute (NCI)
Phase 3BB
DACARBAZINE
National Cancer Institute (NCI)
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Nivolumab
National Cancer Institute (NCI)
Phase 3BB
PEGFILGRASTIM
National Cancer Institute (NCI)
Phase 3B

View all 11 →

Same molecule, other indications

Brentuximab Vedotin is also rated in:

T-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
anaplastic large cell lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →